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Abstract In 2005, a European expert panel developed and
validated an electronic tool to support the appropriate
referral of patients with Parkinson’s disease (PD) for the
consideration of deep brain stimulation (DBS). Since new
evidence has become available over the last decade an update
of the tool is necessary. A world-wide expert panel (71
neurologists and 11 neurosurgeons) used the RAND/UCLA
Appropriateness Method to assess the appropriateness of
referral for 1296 scenarios (9-point scale). Scenarios were
permutations of 8 clinical variables relevant to the decision
of referral. Appropriateness of referral was calculated on the
basis of the median score and the extent of agreement.
Compared to 2005, the impact of clinical variables on the
appropriateness of referral was similar for severity of on–off
fluctuations, dyskinesias and refractory tremor (positive
association, p\ 0.001), and cognitive impairment (negative
association, p\ 0.001). A relatively stronger negative
impact was seen for levodopa-unresponsive gait and balance
disturbances as well as older age, the latter most likely due to
a higher cut-off value (75 versus 70 years in the previous
study). The impact of PD duration on the appropriateness of
referral was less pronounced than in 2005. The contribution
of the newly included variable ‘non-motor side effects of
anti-PD medication’ was very modest. Based on these results
the panel produced new recommendations on the appropri-
ateness of referral for the evaluation of DBS in PD patients.
Differences from the previous study reflect the new clinical
evidence, particularly related to the use of DBS in an earlier
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Introduction
Deep brain stimulation (DBS) is an established treatment for
well-selected patients with Parkinson’s disease (PD) [1, 2].
Patient eligibility for DBS is determined by rigorous and
standardised evaluation in specialised surgical movement
disorder centres. However, patient pre-selection by non-spe-
cialised neurologists or other physicians is often not optimal
due to lack of criteria or guidelines that are easy to use in daily
practice. This may lead to inappropriate referrals [3, 4] but
also to under-referrals if potentially eligible candidates are not
given the opportunity to be evaluated in a specialised centre. A
recent Swedish survey has revealed that three quarters of
patients with advanced PD were not even informed of the
possibility of having DBS therapy by their neurologists [5].
In 2005 a European expert panel used the RAND/UCLA
Appropriateness Method (RUAM) [6] to develop patient-
specific referral criteria for DBS consideration in patients
with PD [7]. These criteria were subsequently embedded in
an online decision support tool (‘‘Stimulus’’) [7]. An
observational study in Germany and Spain showed that the
selection rate for DBS was significantly higher for patients
in which the Stimulus tool had been used compared to the
unscreened population (77 versus 48 %, respectively) [8].
A recent single-centre study in the USA showed that
Stimulus was superior to another tool in predicting DBS
candidacy in patients with PD [9].
Over the last few years new evidence has become available
on the efficacy of DBS, particularly in an earlier stage of PD
[10], and with respect to non-motor fluctuations and symp-
toms, comprising fluctuations of mood and impulse control
disorders [11]. These important data needed to be incorpo-
rated into an update of the Stimulus recommendations and the
online tool. Given the world-wide application of DBS in PD, a
global approach targeting at broadly applicable criteria was
adopted. The aim of this study was to update the 2005 referral
criteria and to develop common recommendations for DBS
consideration in patients with PD.
Methods
Selection of panellists and construction of clinical
scenarios
Similar to the European study [7], the RUAM [6, 12] was
used to establish patient-specific referral criteria. An
Executive Committee, consisting of three neurologists
(EM, TW, and MS) and a methodologist (HS) prepared the
study design (Fig. 1). Three of the executive committee
members were previously involved in the European study
[7]. Panellists were recruited from a worldwide network of
DBS implanting centres. The principal selection criterion
was their active involvement in the selection of at least 15
patients with PD for DBS annually. Furthermore, a rea-
sonable geographic spread was pursued. In total, 146
neurologists and 29 neurosurgeons received an invitation
by email of whom 121 (69 %) responded. Of this group,
105 physicians (87 %) agreed to participate.
Clinical scenarios were based on those of the European
study [7] with some adaptations and refinements. Scenarios
were permutations of the values of eight variables con-
sidered relevant to the decision of referral (Table 1).
Principal changes in comparison to the 2005 study were the
adapted categories for age and PD duration, and the addi-
tion of the variable ‘non-motor side effects of anti-PD
medication’ (Table 1). The population considered was
restricted to patients who met the absolute criteria for DBS
(Table 1).
Panel process
The typical RUAM process consists of individual rating
rounds and plenary face-to-face discussions [12]. The large
size of our panel and the involvement of people from all
over the world necessitated some practical adaptations,
such as web conferences for the plenary meetings (Fig. 1).
Panellists used an online programme to individually
rate the appropriateness of referral for 1296 different
scenarios. The appropriateness scale ranged from 1 (ex-
tremely inappropriate) to 9 (extremely appropriate) with
5 being ‘uncertain’ or ‘equivocal’. Ratings had to be
based on medical considerations only, and economic
aspects had to be disregarded. Instructions to the ratings
were accompanied by an overview of key peer-reviewed
publications regarding DBS therapy for PD. After the
ratings had been completed, data were analysed for
patterns of appropriateness in relation to the clinical
variables used.
A selection of 11 participants (Review Panel; ‘‘Ap-
pendix 1’’) convened in Germany (November 2013) to
discuss the results and to prepare a follow-up web con-
ference for all panel members (January 2014). Thereafter,
panellists were asked to review all their first round results
and to adjust the values if thought to be necessary.
Classification of appropriateness and statistical
analysis
Classification of appropriateness was based on mathemat-
ical rules typically applied in RAND/UCLA
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clinical scenarios panel members
• Individual (online) assessment of the appropriateness of 





• Discussion on 1st round results
•
• Review of 1st
•
support tool
Fig. 1 Study design
Table 1 Definition of terms and variables/categories used for the construction of clinical scenarios
Absolute criteria for the consideration of DBS
Parkinson’s disease for at least 4 years
Presence of bothersome disease-related symptoms (motor fluctuations, dyskinesias, persisting tremor) and/or side effects related to anti-
parkinsonian medication (hyperdopaminergic, anticholinergic)
Motor improvement with dopaminergic medication or presence of medically refractory tremor
Absence of medical conditions preventing surgery (e.g., terminal cancer, severe cardio-respiratory insufficiency)
Absence of ongoing severe, medically resistant neuropsychiatric diseases (e.g., severe depression, severe cognitive impairment)
Referral
Referral for the detailed evaluation of DBS therapy in patients with PD
Irrespective of the target (subthalamic nucleus, globus pallidus pars interna, ventral intermediate nucleus of the thalamus)
Variables used for the construction of clinical scenarios
Age (\60 years; 60–74 years; C75 years)a
PD duration since onset of symptoms (4–7 years; C7 years)b
Parkinsonian signs during OFF periods, despite medical treatment (no–mild; moderate; severe impact on activities of daily living)
Dyskinesias (no–mild; moderate; severe impact on activities of daily living)
Tremor unresponsive to or requiring unacceptably high doses of anti-parkinsonian medication (no–mild; moderate; severe impact on
activities of daily living)
Levodopa-unresponsive gait and balance abnormalities (no; yes)
Cognitive impairment (no–mild; moderate)
Non-motor side effects of anti-parkinsonian medication (no–mild; moderate–severe)c
a Age categories in 2005:\60 years; 60–69 years; C70 years
b PD duration categories in 2005:\5 years; C5 years
c Not included as a variable in 2005
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appropriateness studies [12]. Referral was classified as
appropriate if the median score was 7–9 without dis-
agreement, and as inappropriate if the median score was
1–3 without disagreement. All other outcomes were
deemed uncertain. Disagreement was defined as the situa-
tion in which at least one-third of the panellists had scored
in each of the extreme sections of the 9-point scale (1–3
and 7–9) [12]. To correct for potential asymmetric ratings,
the disagreement calculations were checked using the
interpercentile range adjusted for symmetry (IPRAS) for-
mula that has been advised for use in large-scale panels
[12]. Logistic regression was used to determine the rela-
tionship between clinical variables and appropriateness of
referral. All statistical analyses were performed using IBM
SPSS for Windows version 22.
Results
Participants and panel process
Of the 105 physicians who agreed to participate, 82 (78 %)
completed all first round ratings. This voting panel con-
sisted of 71 neurologists and 11 neurosurgeons from 28
countries (‘‘Appendix 1’’). Ninety-four percent reported
C5 years of experience with patient selection for DBS, and
51 % mentioned to be involved in at least 25 evaluations
annually. The first online rating round was conducted in
October–November 2013. Panellists needed on average
3–4 h for completing the ratings. Discussion of the results
by the Review Panel and during the web conference
revealed that the structure and variables were adequate, but
that different perspectives had been used while doing the
ratings (appropriateness of DBS versus the appropriateness
of referral). Panellists were asked to review all ratings
taking the perspective of appropriateness of referral as the
starting point. Second round ratings were completed in
April 2014.
Agreement and appropriateness
Using the RUAM classical calculation, disagreement after
the second round was found for only two out of 1296
scenarios (0.2 %). Application of the IPRAS formula
resulted in disagreement for 1.2 % of scenarios. However,
the two approaches never led to different appropriateness
outcomes.
Referral for DBS consideration was deemed inappro-
priate for 15 % of the scenarios, appropriate for 46 % of
the scenarios, and uncertain for the remaining 39 %.
Appropriateness figures by clinical variables are given in
Table 2. Logistic regression analysis (appropriate versus
uncertain/inappropriate) revealed a consistent pattern of
factors determining the appropriateness of referral (pre-
dictive value 96.5 % at a cut-off value of 0.5). Whereas the
severity of OFF symptoms, dyskinesias and tremor showed
a pronounced positive association with appropriateness, a
negative impact was found for cognitive impairment,
levodopa-unresponsive gait and balance problems, and
higher age (Table 3).
Though statistically significant, the contribution of PD
duration and presence of non-motor side effects of
antiparkinsonian medication was small. No meaningful
interaction effects between the variables, including age and
PD duration, were seen.
Differences by subgroups of raters
Neurosurgeons showed higher rates for referral consider-
ation than neurologists (61 versus 43 %; p\ 0.001); sim-
ilar figures were seen for the Review Panel (59 %) versus
other participants (43 %; p\ 0.001). Variations by geo-
graphic regions could not be assessed due to the small
number of participants per area.
Online educational tool
Panel results were embedded in an online tool that allows
the user to select a patient profile and to see the related
panel recommendation and additional information on
patient selection for DBS. The tool can be freely accessed
via https://www.earlystimulus.com.
Discussion
Our study provides practical criteria to reduce inappropri-
ate referrals and to support referral of appropriate candi-
dates for DBS in patients with PD. This is particularly
relevant since there is a strategic need for physicians and
patients to improve the process quality of PD referrals for
DBS.
The previously developed Stimulus tool has been shown
to be able to considerably improve the quality of pre-se-
lection by referral neurologists [8, 9]. The current study has
not only updated the referral criteria taking into account
new evidence from recent clinical studies [10, 11], but it
has also received wide feedback for a worldwide applica-
bility by involving expert neurologists and neurosurgeons
from many countries around the world. Although some
differences by subgroups were seen, this large-scale panel
reached considerable agreement on the appropriateness of
referral for DBS consideration in patients with PD. The
relatively large area of uncertainty (39 % of indications)
was not due to opposite opinions, but to ‘‘middle-of-the-
road’’ ratings reflecting situations in which potential
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advantages and drawbacks of referral were considered to
be equivocal. However, the appropriateness figures relate
to a theoretical population, and the distribution of clinical
scenarios in real-life practice may differ considerably.
Moreover, some scenarios may reflect frequent
constellations whereas others may be rather ‘‘constructed’’
and rarely seen in daily clinical practice.
Regression analysis showed consistent and logical
associations between the clinical variables and appropri-
ateness outcomes. As no meaningful interaction effects
Table 2 Appropriateness of
referral for DBS by clinical
variables
Variable Categories Inappropriate % Uncertain % Appropriate % p valuea
Age \60 years 2 30 68 \0.001
60–74 years 3 40 57
C75 years 41 47 12
PD duration 4–7 years 16 40 44 0.279
C7 years 15 38 48
OFF symptoms Mild 22 41 38 \0.001
Moderate 15 41 45
Severe 10 36 55
Dyskinesias Mild 24 39 38 \0.001
Moderate 14 43 43
Severe 9 35 57
Tremor No/mild 25 41 35 \0.001
Moderate 15 42 43
Severe 7 34 59
Gait/balance problems No 9 26 65 \0.001
Yes 22 52 26
Cognitive impairment No/mild 6 28 66 \0.001
Moderate 25 50 26
Non-motor side effects No/mild 18 39 44 0.085
Moderate-severe 13 39 48
Percentages apply to the complete set of clinical scenarios (N = 1296)
Row totals per variable are 100 %, but may slightly deviate due to round-offs
a Pearson’s Chi-square test for categorical data




Variable Value b SE p value
Age 60–74 years -2.64 0.41 \0.001
C75 years -16.06 1.42
PD duration C7 years 1.27 0.32 \0.001
OFF symptoms Moderate 1.97 0.40 \0.001
Severe 4.89 0.55
Dyskinesias Moderate 1.53 0.38 \0.001
Severe 5.47 0.59
Refractory tremor Moderate 2.10 0.38 \0.001
Severe 7.25 0.72
Levodopa-unresponsive gait/balance abnormalities Yes -11.34 1.02 \0.001
Non-motor side effects of anti-parkinsonian medication Moderate–severe 1.09 0.31 \0.001
Cognitive impairment Moderate -11.60 1.04 \0.001
Constant value 7.04 0.85
Outcomes of logistic regression analysis
Reference classes for regression: age:\60 years; PD duration: 4–7 years; OFF symptoms: mild; Dyski-
nesias: mild; Refractory tremor: no/mild; Levodopa-unresponsive gait/balance abnormalities: no; Non-
motor side effects of anti-parkinsonian medication: no/mild; Cognitive impairment: no/mild
116 J Neurol (2016) 263:112–119
123
were detected, the impact of the variables on appropriate-
ness of referral for DBS was merely cumulative. That
means that the sum of positive and negative factors, with
their different weights, determines the appropriateness
category. To illustrate this result, the panel outcomes (ap-
propriateness category and median score) for five selected
profiles are projected against the patient characteristics in
Fig. 2.
The comparison with the results from our previous study
[7] suggests similar patterns for the impact of the severity
of OFF symptoms, dyskinesias and refractory tremor
(positive association), as well as of cognitive impairment
(negative association). In this current study, a relatively
stronger negative impact was seen for older age and
levodopa-unresponsive gait and balance disturbances. For
older age, the difference is most likely to be ascribed to the
higher cut-off value (75 versus 70 years in the previous
study) as the general trend goes to including older patients.
With the new clinical evidence showing the benefits of
DBS at an earlier stage of PD [10, 13], criteria of DBS
selection concerning PD duration and severity have chan-
ged. This is reflected in the less pronounced impact of PD
duration on the appropriateness of referral in our study in
comparison to the view of the initial panel [7]. The panel
ratings also indicate that these recent findings on the effect
of early surgical treatment [10] are readily implemented by
experts worldwide in spite of a controversial debate on this
topic [14, 15].
As evidence became available that DBS may also be
useful in improving non-motor side effects of anti-
parkinsonian medication [11, 16], we included this condi-
tion in the construction of clinical scenarios. However, its
impact on the appropriateness of referral, though statisti-
cally significant in multivariate logistic regression, was
very modest. This finding could reflect the insufficient
distinction made by neurologists between hyperdopamin-
ergic behavior induced by anti-PD medications (that is
supposed to improve with subthalamic nucleus (STN) DBS
due to reduction of medications) and impulsivity occa-
sionally induced by STN DBS (that may occur under
inappropriate STN-DBS programming) [17].
Other factors used by the panel study, including the
absolute criteria for the consideration of DBS for PD
(bothersome symptoms, motor improvement with
dopaminergic medication or presence of medically refrac-
tory tremor, absence of medical conditions preventing
surgery, absence of severe medically resistant neuropsy-
chiatric diseases) are comparable to the initial study [7] and
have not undergone substantial changes over the last dec-
ade [18, 19].
The dissemination of the panel recommendations via a
quick and user-friendly online tool has already proven its
usefulness in a European setting [8]. The new updated tool,
established now with the involvement of a world-wide
panel, may have a larger geographic reach and impact.
However, the authors’ personal experience with the first
Stimulus tool has shown that users frequently misinter-
preted an appropriate outcome as being synonymous to
‘‘eligible for DBS’’. Therefore, we would like to emphasise
that the tool is designed to assess the appropriateness of
Fig. 2 Panel outcomes for
selected patient profiles
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referral to a specialised DBS centre for further evaluation,
and not for surgery itself.
The most important limitations of this study are related
to the subjective nature of the panel opinions, and selection
of panel members may, therefore, influence the outcomes.
Indeed, new published guidelines or consensus about
selection of patients for DBS are still lacking, despite the
available evidence concerning efficacy of DBS on earlier
PD stages and on non-motor fluctuations. However, various
studies have shown that agreement between RUAM panels
of similar composition, even if from different countries or
continents, is usually satisfactory to good [20–23]. Com-
parison of our initial and current study into DBS/PD con-
firms on the one hand the reproducibility of the study
results over time and across countries, but also suggests
sensitivity to change in scientific insights.
In conclusion, patient eligibility for DBS is determined
in specialised surgical centres following a rigorous and
extensive evaluation that is often challenging for the
patient and the family, both physically and emotionally.
The use of clear and practical criteria for pre-selection by
general neurologists or other physicians may reduce the
number of inappropriate referrals, and may also help to
avoid under-referral of potentially appropriate candidates.
A large world-wide panel has produced detailed and con-
sistent recommendations on the appropriateness of referral
for the consideration of DBS in patients with PD. Differ-
ences in comparison to the initial panel study reflect new
clinical evidence, particularly in relation to the use of DBS
in an earlier stage of PD. The use of a simple online tool
may help to disseminate the panel recommendations and to
increase the quality of pre-selection for DBS. Research on
validating the updated recommendations is in progress.
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